PT - JOURNAL ARTICLE AU - Sohaib Ashraf AU - Shoaib Ashraf AU - Moneeb Ashraf AU - Muhammad Ahmad Imran AU - Larab Kalsoom AU - Uzma Nasim Siddiqui AU - Iqra Farooq AU - Zaighum Habib AU - Sidra Ashraf AU - Muhammad Ghufran AU - Muhammad Kiwan Akram AU - Nighat Majeed AU - Zain-ul-Abdin AU - Rutaba Akmal AU - Sundas Rafique AU - Khawar Nawaz AU - Muhammad Ismail K Yousaf AU - Sohail Ahmad AU - Muhammad Sarmad Shahab AU - Muhammad Faisal Nadeem AU - Muhammad Azam AU - Hui Zheng AU - Amber Malik AU - Mahmood Ayyaz AU - Talha Mahmud AU - Qazi Abdul Saboor AU - Ali Ahmad AU - Muhammad Ashraf AU - Mateen Izhar AU - for the COALITION COVID-19 Shaikh Zayed AU - Abubakar Hilal AU - Arz Muhammad AU - Zeeshan Shaukat AU - Ayesha Khaqan AU - Kanwal Hayat AU - Shahroze Arshad AU - Muhammad Hassan AU - Abeer-bin-Awais AU - Ammara Ahmad AU - Tayyab Mughal AU - Abdur Rehman Virk AU - Muhammad Umer AU - Muhammad Suhail AU - Sibgha Zulfiqar AU - Saulat Sarfraz AU - Muhammad Imran Anwar AU - Ayesha Humayun AU - R A Khokhar AU - S Siddique TI - Honey and <em>Nigella sativa</em> against COVID-19 in Pakistan (HNS-COVID-PK): A multi-center placebo-controlled randomized clinical trial AID - 10.1101/2020.10.30.20217364 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.30.20217364 4099 - http://medrxiv.org/content/early/2020/11/30/2020.10.30.20217364.short 4100 - http://medrxiv.org/content/early/2020/11/30/2020.10.30.20217364.full AB - BACKGROUND No definitive treatment exists for Coronavirus Disease 2019 (COVID-19). Honey and Nigella sativa (HNS) have established antiviral, antibacterial, anti-inflammatory and immunomodulatory properties. Hence, we investigated efficacy of HNS against COVID-19. wideMETHODS We conducted a multicenter, placebo-controlled, randomized clinical trial at 4 centers in Pakistan. RT-PCR confirmed COVID-19 adults showing moderate or severe disease were enrolled in the study. Patients presenting with multi-organ failure, ventilator support, and chronic diseases (except diabetes mellitus and hypertension) were excluded. Patients were randomly assigned in 1:1 ratio to receive either honey (1 gm/Kg/day) and Nigella sativa seeds (80 mg/Kg/day) or placebo up-to 13 days along with standard care. The outcomes included symptom alleviation, viral clearance, and a 30-day mortality in intention-to-treat population. This trial was registered with ClinicalTrials.gov, NCT04347382.RESULTS Three hundred and thirteen patients - 210 moderate and 103 severe - underwent randomization from April 30 to July 29, 2020. Among these, 107 were assigned to HNS whereas 103 to placebo for moderate cases. For severe cases, 50 were given HNS and 53 were given placebos. HNS resulted in ∼50% reduction in time taken to alleviate symptoms as compared to placebo (Moderate (4 versus 7 days), Hazard Ratio [HR]: 6.11; 95% Confidence Interval [CI]: 4.23-8.84, P&lt;0.0001 and severe (6 versus 13 days) HR: 4.04; 95% CI, 2.46-6.64, P&lt;0.0001). HNS also cleared the virus 4 days earlier than placebo group in moderate (6 versus 10 days, HR: 5.53; 95% CI: 3.76-8.14, P&lt;0.0001) and severe cases (8.5 versus 12 days, HR: 4.32; 95% CI: 2.62-7.13, P&lt;0.0001). HNS further led to a better clinical score on day 6 with normal activity resumption in 63.6% versus 10.9% among moderate cases (OR: 0.07; 95% CI: 0.03-0.13, P&lt;0.0001) and hospital discharge in 50% versus 2.8% in severe cases (OR: 0.03; 95% CI: 0.01-0.09, P&lt;0.0001). In severe cases, mortality rate was four-fold lower in HNS group than placebo (4% versus 18.87%, OR: 0.18; 95% CI: 0.02-0.92, P=0.029). No HNS-related adverse effects were observed.CONCLUSION HNS significantly improved symptoms, viral clearance and mortality in COVID-19 patients. Thus, HNS represents an affordable over the counter therapy and can either be used alone or in combination with other treatments to achieve potentiating effects against COVID-19.FUNDING Funded by Smile Welfare Organization, Shaikh Zayed Medical Complex, and Services Institute of Medical Sciences.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04347382Funding StatementFunded by Smile Welfare Organization, Shaikh Zayed Medical Complex and Services Institute of Medical SciencesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB Shaikh Zayed Post-Graduate Medical Institute, Lahore, Pakistan approval ID SZH/IRB/0026/2020 and IRB Services Institute of Medical Sciences, Lahore, Pakistan approval ID IRB/2020/658/SIMSAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesClinical data is available as additional file and raw data can be provided on request to corresponding author